Overview: Anticancer Monoclonal Antibodies: Recent Developments

References

• LEVY RL, MILLER RA: Biological and clinical implications of lymphocyte hybridomas: tumor therapy with monoclonal antibodies. Annual Rev. Med. (1983) 34:107–116.
   PubMed Web of Science ®Google Scholar
• ScHROFF RW, FOON KA, BEATTY SM, OLDHAM RK, MORGAN AC: Human anti-murine im-munoglobulin responses in patients receiv-ing monoclonal antibody therapy. Cancer Res. (1985) 45:879–885.
   Google Scholar
• LOBUGLIO AF, SALEH M, PETERSON L, WHEELER R, CARRANCO R, HUSTER W, KHAZAELI MB: Phase I clinical trial of C017-1A monoclonal antibody. Hybridoma (1986) 5 (suppl. I):s117.
   Google Scholar
• COURTINAY-LUCK NS, EPENETOS AA, MOORE R, LARCHE M, PECTASIDES D, DHOIUA B, RTTTER MA: Development of primary and secondary immune responses to mouse mon-oclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. (1986) 46:6489–6493.
   Google Scholar
• PRIMUS FJ, BENNETT SJ, KIM EF, DELAND FH, ZAHN MC, GOLDENBERG DM: Circu-lating immune complexes in cancer pa-tients receiving goat radiolocalizing antibod-ies to carcinoembryonic antigen. Cancer Res. (1980) 40:497–501.
   Google Scholar
• Liu A, ROBINSON R, HELLSTROM DE, MURRAY ED, CHANG CP JR, HELLSTROM I: Chimeric mouse-human IgG1 antibody that can me-diate lysis of cancer cells. Proc. Natl. Acad. Sci USA (1987) 84:3439–3443.
   PubMed Web of Science ®Google Scholar
• SUN LK, CRETIS P. RAKOWICZ-SZULCZYNSKA E, GHRAYEB J, CHANG N, MORRISON SE KOPROWSKI H: Chimeric antibody with hu-man constant regions and mouse variable regions directed against carcinoma-associ-ated 17-1A. Proc. Nat. Acad. Sci. USA (1987) 84:214–218.
   PubMed Web of Science ®Google Scholar
• LOBUGLIO AF, WHEELER RJ, TRANG J, HAYNES A, ROGERS K, HARVEY EB, SUN L, GHRAYEB J, KHAZAELI MB: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Nat. Acad. Sci. USA (1989) 86:4220–4224.
   PubMed Web of Science ®Google Scholar
• XIANG J, CHEN Z: Genetic engineering of high affinity anti-human colorectal tumor mouse/human chimeric antibody. Immunol. (1992) 75:205–216.
   Google Scholar
• RIECHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (London) (1988) 332:323–327.
   PubMed Web of Science ®Google Scholar
• BIRD RE, HARDMAN KD, JACOBSON JW, JOHNSON S, KAUFMAN BM, TEE S-M, TEE T, POPE SIT, RIORDAN GS, WHITLOW M: Single-chain antigen-binding proteins. Sci-ence (1988) 242:423–426.
   PubMed Web of Science ®Google Scholar
• HUSTON JS, LEVINSON D, MUDGETT-HUNTER T, TM MS, NOVOTNY J, MARGOLES MN, RIDGE RI, BRUCCOLERI RE, HABER E, CREA R, OPPERMANN H: Protein engineering of an-tibody binding sites: Recovery of specific activity in an anti-digoxin single chain Fv analogue produced in Escherichia coli. Proc. Nat. Acad. Sci. USA (1988) 85:5879–5883.
   PubMed Web of Science ®Google Scholar
• SELL S: Cancer markers of the 1990s. Clin. Lab. Med. (1990) 10:1–37.
   PubMedGoogle Scholar
• HERLYN H, MENRAD A, KOPROWSKI H: Struc-ture, function and clinical significance of hu-man tumor antigens. J. Natl. Cancer Inst. (1990) 82:1883–1889.
   PubMed Web of Science ®Google Scholar
• BALLOU B, LEVINE G, HAKALA RR, SOLTER D: Tumor location detected with radioactiv-ity labeled monoclonal antibody and exter-nal scintigraphy. Science (1979) 206:844–847.
   PubMed Web of Science ®Google Scholar
• MACH JP, BUCHEGGAN F, FORM M, RTTSCHARD J, BERCHE C, LUMBRUSO ID, SCHREYER M, GIRARDET C, ACCOLA RS, CARREL S. Use of radiolabeled monoclonal anti-CEA antibod-ies for the detection of human carcinomas by external photoscanning and tomoscintigra-phy. Immunol. Today (1981) 2:239–248.
   PubMedGoogle Scholar
• GRIFFITHS GL, GOLDENBERG DM, JONES AL, HANSIN HL: Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjugate Chem. (1992) 3:91–99.
   PubMed Web of Science ®Google Scholar
• QUIN-TONES J, MIZEJEWSKI G, BEIERWALTER WH: Choriocarcinoma scanning using radio-labeled antibody to chorionic gonadotropin. J. Nucl. Med. (1971) 12:69–75.
   Google Scholar
• GOLDENBERG DM, PRESTON DF, PRIMUS FJ, HANSIN HJ: Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglob-ulin G. Cancer Res. (1974) 34:1–9.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG DA, STRAND M: Leukemic cell targeting and therapy by monoclonal anti-body in a mouse model system. Cancer Res. (1982) 42:44–49.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG DA, STRAND M, GANSOW OA: Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Sci ence (1982) 215:1511–1513.
   PubMed Web of Science ®Google Scholar
• DELAND FH, KIM EF, SIMMONS G, GOLDENBERG DM: Imaging approach in radioimmunode-tection. Cancer Res. (1980) 40:3046–3049.
   PubMed Web of Science ®Google Scholar
• WAHL RL, PARKER CW, PHILPOTT GW: Im-proved radioimaging and tumor localiza- tion with monoclonal F(ab')2. J. Nucl. Med. (1983) 24:316 325.
   Google Scholar
• BEGFNT RHJ, GREEN Al, BAGSHAWE KD, JONES BE, KEEP PA, SEARLE F, JEWKES RF, BARRALT GM, RYMAN BE: Liposomally en-trapped second antibody improves tumour imaging with radiolabeled (first) antitumour antibody. Lancet (1982) 2:739–742.
   Google Scholar
• STELS RG, CARRASQUILLO J A, MCCABE R, BOOICMAN MA, REYNOLDS JC, LARSON SM, SMITH JW, CLARK JW, DAILEY V. DEL VECCHIO S, ET AL.: Toxicity, immunogenicity and tu-mor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J. Clin. Oncol. (1990) 8:476–490.
   Google Scholar
• GOLDENBERG DM: Future role of radiola-beled monoclonal antibodies in oncologi-cal diagnosis and therapy. Sem. Nucl. Med. (1989) 19:332 339.
   Google Scholar
• VOGEL CW: Immunoconjugates: Antibody conjugates in radioimaging and therapy of cancer. (1987) Oxford University Press, New York.
   Google Scholar
• IIERMENTIN P. SEILER FR: Investigations with monoclonal antibody drug (anthracycline) conjugates. Behring Inst. Mitt (1988) 82:197–215.
   Google Scholar
• STARLING JJ, MACIAK RS, HINSON NA, NICHOL CL, BRIGGS SL, LAGUZZA BC: In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody. Cancer Im-munol. Immunother. (1989) 28:171–178.
   PubMedGoogle Scholar
• FRANKEL, E: Immuotoxins. (1988) Kluwer Aca-demic Publishers, Boston.
   Google Scholar
• BLAKEY SC, WAWRZYNCZAK El, WALLACE PM, THORPE PE: Antibody toxin conjugates: A perspective. Prog. Allergy (1988) 45:50–90.
   PubMedGoogle Scholar
• PEARSON JW, HEDRICK E, FOGLER WE, BULL RL, FERRIS RK, RIGGS CW, WILTROUT RH, SWAN G, MORGAN AC, GROVES E,ET AL.: En-hanced therapeutic efficacy against an ovar-ian tumor xenograft of immunotoxins used in conjugation with a recombinant alpha-in-terferon. Cancer Res. (1990) 50:6739–6788.
   Google Scholar
• SCHLOM J: Basic principles and applications of monoclonal antibodies in the manage-ment of carcinomas: The Richard and Hinda Rosenthal foundation award lecture. Cancer Res. (1986) 46:3225–3228.
   PubMed Web of Science ®Google Scholar
• LEDOUSSAL JM, GRUAZ-GUYON A, MARTIN M, GAUTHEROT E, DELAAGE M, BARBET J: Targeting of indium Ill-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Can-cer Res. (1990) 50:3445–3452.
   Google Scholar
• SFNTER PD: Activation of prodrugs by antibody-enzyme conjugates. A new ap-proach to cancer therapy. FASEB J. (1990) 4:188–193.
   Google Scholar
• SVENSSON HP, KADOW JF, VRUDHULA VM, WALLACE PM, SFNTER PD: Monoclonal antibody-p"-lactamase conjugates for the ac-tivation of a cephalosporin mustard pro-drug. Bioconjugate Chem. (1992) 3:176–181.
   PubMed Web of Science ®Google Scholar
• BAGSHAWE KD, SPRINGER CJ, SEARLE F, ANTONIW P. SHARMA SK, MELTON RF: A cy-totoxic agent can be generated at cancer sites. Br. J. Cancer (1988) 58:700–703.
   PubMed Web of Science ®Google Scholar
• SFNTER PD, SCHREIBER GJ, HIRSCHBERG DL, ASHE SA, HELLSTROM KE, HELLSTROM I: Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mito-mycin C and ectoposide derivatives by mon-oclonal antibody-alkaline phosphatase con-jugates. Cancer Res. (1989), 49:5789–5792.
   Google Scholar
• KERR DE, SFNTER PD, BURNETT WV, HIRSCH-BERG DL, HELLSTROM I, HELLSTROM ICE: Antibody-penicillin-V-amidase kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Im-munol. Immunother. (1988) 85:4842–4846.
   Google Scholar
• KOPROWSICE H, HERLYN D, LUBECK M, DEFREITAS E, SEARS HF: Human antiidio-type antibodies in cancer patients: is the modulation of the immune response bene-ficial for the patient? Proc. Natl. Acad. Sci. USA (1984) 81:216–219.
   Google Scholar
• RICHARDS JM, VOGELZANG NJ, BLUESTONE JA: Neurotoxicity after treatment with muromonoab-CD3. N. Engl. J. Med. (1990) 323:487–488.
   Google Scholar
• GILLIES SD, REILLY EB, LO KM, RELSFELD RA: Antibody-targeted interleukin 2 stimu-lates T-cell killing of autologous tumor cells. Proc. Natl. Acad. Sci. USA (1992) 89:1428–1432.
   PubMed Web of Science ®Google Scholar
• SHALABY MR, SHEPARD BM, PRESTA L, RODRIGUES ML, BEVERLY PCL, FELDMAN M, CARTER P: Development of humanized bispe-cific antibodies reactive with cytotoxic lym-phocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. (1992)1752 17–225
   Google Scholar